AbbVie’s clash with an adalimumab biosimilar producer is the latest in a string of lawsuits showing why biologics originators and imitators need strategies to protect proprietary information
AbbVie’s clash with an adalimumab biosimilar producer is the latest in a string of lawsuits showing why biologics originators and imitators need strategies to protect proprietary information